Imiquimod 5% cream for the treatment of periocular basal cell carcinoma

Ophthalmic Plastic and Reconstructive Surgery

Volumn 26, Issue 2, 2010, Pages 100-102

  Carneiro, Rachel Camargo ^a   De MacEdo, Erick Marcet Santiago ^a   Matayoshi, Suzana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EYELID CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; EYELID NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PILOT PROJECTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77949930463     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/IOP.0b013e3181b8dd71     Document Type: Article

References (14)

1. Salomon J, Bieniek A, Baran E, Szepietowski JC. Basal cell carcinoma on the eyelids: own experience. Dermatol Surg 2004; 30(2 Pt 2):257-263
2. Macedo EMS, Carneiro RC, Matayoshi S. Nova modalidade no tratamento do carcinoma basocelular periocular: imiquimode. New approach to periocular basal cell carcinoma treatment: imiquimod. Rev Bras Oftalmol 2007;66:411-417
3. Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2007;245: 1217-1220
4. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:722-733
5. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005;152:939-947
6. Gupta AK, Browne M, Bluhm R. Imiquimod: a review. J Cutan Med Surg 2002;6:554-560
7. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol 2003; 139:1347-50; comment on Arch Dermatol 2003;139:1325-1332
8. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005;31:318-323
9. Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen,s disease. J Am Acad Dermatol 2001;44:462-470
10. Roseeuw D. The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum. Clin Exp Dermatol 2003; 28(Suppl 1):30-32
11. Leppälä J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007;85:566-568
12. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139:1325-32; comment in Arch Dermatol 2003;139:1347-1350
13. Blasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol 2005;140:1136-1139
14. Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 2007;57:616-621